Merck & Co., Inc., Kenilworth, NJ, USA (NYSE: MRK), known as MSD outside the United States and Canada, announced that Organon & Co. will be the name of a new company to be created through the intended spinoff of its women’s health, trusted legacy brands and biosimilars businesses. Fueled by its leading contraceptives and fertility businesses, Organon will invest in innovations that support the distinct health care needs of women today. Organon will also focus on its important biosimilars business, focusing on oncology and inflammatory diseases, while also maximizing the value of its trusted dermatology, pain, respiratory and cardiovascular portfolio in countries around the world where there is still great need for these treatments. Usage of the new company logo and brand is effective upon completion of the spinoff in the first half of 2021.